Literature DB >> 1938702

Opportunistic and pathogenic fungi.

M D Richardson1.   

Abstract

The number of fungal species reported to cause disease in man is increasing rapidly. Very few of these fungi are capable of infecting a normal host. Important progress has been achieved in an understanding of fungal pathogenicity including the mechanisms of adherence to host tissues, penetration of tissues, multiplication within the host, and the interaction of fungal cells with host effector cells. In addition to the increase in infections by opportunistic and pathogenic fungi in compromised patients, caused by Candida spp., Aspergillus spp., Cryptococcus neoformans, Histoplasma capsulatum and Coccidioides immitis, many fungi that occur as saprophytes in the environment and which had previously been considered to be nonpathogenic are now being encountered as causes of human infection. The advent of these unusual infections has led to reappraisal of the diagnostic tests involved in the investigation of fungal infections and has had important implications for the choice of treatment. Many of these fungi have a similar tissue appearance and the organisms must be isolated and identified to ensure that the most appropriate treatment is given.

Entities:  

Mesh:

Year:  1991        PMID: 1938702     DOI: 10.1093/jac/28.suppl_a.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

1.  Oral colonization, phenotypic, and genotypic profiles of Candida species in irradiated, dentate, xerostomic nasopharyngeal carcinoma survivors.

Authors:  W K Leung; R S Dassanayake; J Y Yau; L J Jin; W C Yam; L P Samaranayake
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 2.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

3.  Analysis of growth characteristics of filamentous fungi in different nutrient media.

Authors:  J Meletiadis; J F Meis; J W Mouton; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

4.  A vitamin-free minimal synthetic medium for Cryptococcus neoformans.

Authors:  V Vidotto; S Aoki; G Campanini
Journal:  Mycopathologia       Date:  1996       Impact factor: 2.574

5.  Phylogeny and PCR identification of clinically important Zygomycetes based on nuclear ribosomal-DNA sequence data.

Authors:  K Voigt; E Cigelnik; K O'donnell
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

6.  Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi.

Authors:  E Herreros; C M Martinez; M J Almela; M S Marriott; F G De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Heterogeneity of the purified extracellular aspartyl proteinase from Candida albicans: characterization with monoclonal antibodies and N-terminal amino acid sequence analysis.

Authors:  C J Morrison; S F Hurst; S L Bragg; R J Kuykendall; H Diaz; J Pohl; E Reiss
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

8.  In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184.

Authors:  J C Fung-Tomc; B Minassian; E Huczko; B Kolek; D P Bonner; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Synthesis and Antimicrobial Activities of His(2-aryl)-Arg and Trp-His(2-aryl) Classes of Dipeptidomimetics.

Authors:  Amit Mahindra; Krishna K Sharma; Dinesh Rathore; Shabana I Khan; Melissa R Jacob; Rahul Jain
Journal:  Medchemcomm       Date:  2014-05-01       Impact factor: 3.597

10.  Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues.

Authors:  Paul Bowyer; Marcin Fraczek; David W Denning
Journal:  BMC Genomics       Date:  2006-10-09       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.